Short Interest in TherapeuticsMD, Inc. (NASDAQ:TXMD) Expands By 1,901.7%

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 240,200 shares, an increase of 1,901.7% from the December 31st total of 12,000 shares. Approximately 2.1% of the company’s shares are sold short. Based on an average trading volume of 286,000 shares, the short-interest ratio is presently 0.8 days.

TherapeuticsMD Price Performance

Shares of TXMD stock remained flat at $1.08 on Friday. 12,606 shares of the stock were exchanged, compared to its average volume of 854,330. TherapeuticsMD has a one year low of $0.70 and a one year high of $2.75. The firm has a 50 day simple moving average of $1.18 and a 200-day simple moving average of $1.49.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $0.55 million for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 14.08%.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on TherapeuticsMD in a report on Tuesday, January 14th. They set a “hold” rating on the stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.